Cerebral Vasoreactivity, Apolipoprotein E, and the Risk of Dementia: A Population-Based Study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 1, 2016, Pages 204-210

  Wolters, Frank J ^a   De Bruijn, Renée F A G ^a   Hofman, Albert ^a   Koudstaal, Peter J ^a   Arfan Ikram, M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer disease; apolipoprotein E; dementia; epidemiology; hypercapnia; vasoreactivity

Indexed keywords

APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG; APOLIPOPROTEIN E4; GENETIC MARKER;

AGED; ALZHEIMER DISEASE; ARTICLE; BODY MASS; CEREBRAL VASOREACTIVITY; COGNITIVE FUNCTION TEST; COHORT ANALYSIS; DEMENTIA; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HYPERCAPNIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM PARAMETERS; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; BRAIN CIRCULATION; COGNITION; DISEASE FREE SURVIVAL; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PATHOPHYSIOLOGY; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL MODEL; STROOP TEST; TIME FACTOR; TRANSCRANIAL DOPPLER ULTRASONOGRAPHY;

AGED; APOLIPOPROTEIN E4; CEREBROVASCULAR CIRCULATION; COGNITION; DEMENTIA; DISEASE-FREE SURVIVAL; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MALE; MIDDLE AGED; NETHERLANDS; ODDS RATIO; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROOP TEST; TIME FACTORS; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 84952639270     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306768     Document Type: Article

References (51)

1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP, The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement 2013 9 63 75.e2. doi: 10.1016/j.jalz.2012.11.007
2. International AD Policy Brief for G8 Heads of Government. The Global Impact of Dementia 2013-2050 [cited 2015 Mar 25]. http://www.alz.co.uk/research/G8-policy-brief
3. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J, Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol 2006 5 735 741. doi: 10.1016/S1474-4422(06)70537-3
4. Ngandu T, Lehtisalo J, Solomon A, A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015 385 2255 2263. doi: 10.1016/S0140-6736(15)60461-5
5. Hall CN, Reynell C, Gesslein B, Hamilton NB, Mishra A, Sutherland BA, O'Farrell FM, Buchan AM, Lauritzen M, Attwell D, Capillary pericytes regulate cerebral blood flow in health and disease. Nature 2014 508 55 60. doi: 10.1038/nature13165
6. Portegies ML, de Bruijn RF, Hofman A, Koudstaal PJ, Ikram MA, Cerebral vasomotor reactivity and risk of mortality: the Rotterdam Study. Stroke 2014 45 42 47. doi: 10.1161/STROKEAHA.113.002348
7. Gupta A, Chazen JL, Hartman M, Delgado D, Anumula N, Shao H, Mazumdar M, Segal AZ, Kamel H, Leifer D, Sanelli PC, Cerebrovascular reserve and stroke risk in patients with carotid stenosis or occlusion: a systematic review and meta-analysis. Stroke 2012 43 2884 2891. doi: 10.1161/STROKEAHA.112.663716
8. Bakker SL, de Leeuw FE, de Groot JC, Hofman A, Koudstaal PJ, Breteler MM, Cerebral vasomotor reactivity and cerebral white matter lesions in the elderly. Neurology 1999 52 578 583
9. Debette S, Markus HS, The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 2010 341 c3666
10. Keage HA, Churches OF, Kohler M, Pomeroy D, Luppino R, Bartolo ML, Elliott S, Cerebrovascular function in aging and dementia: a systematic review of transcranial Doppler studies. Dement Geriatr Cogn Dis Extra 2012 2 258 270. doi: 10.1159/000339234
11. Yezhuvath US, Uh J, Cheng Y, Martin-Cook K, Weiner M, Diaz-Arrastia R, van Osch M, Lu H, Forebrain-dominant deficit in cerebrovascular reactivity in Alzheimer's disease. Neurobiol Aging 2012 33 75 82. doi: 10.1016/j.neurobiolaging.2010.02.005
12. den Abeelen AS, Lagro J, van Beek AH, Claassen JA, Impaired cerebral autoregulation and vasomotor reactivity in sporadic Alzheimer's disease. Curr Alzheimer Res 2014 11 11 17
13. Jespersen SN, Østergaard L, The roles of cerebral blood flow, capillary transit time heterogeneity, and oxygen tension in brain oxygenation and metabolism. J Cereb Blood Flow Metab 2012 32 264 277. doi: 10.1038/jcbfm.2011.153
14. Eltzschig HK, Carmeliet P, Hypoxia and inflammation. N Engl J Med 2011 364 656 665. doi: 10.1056/NEJMra0910283
15. Block ML, Zecca L, Hong JS, Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007 8 57 69. doi: 10.1038/nrn2038
16. Grammas P, Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J Neuroinflammation 2011 8 26. doi: 10.1186/1742-2094-8-26
17. Vukic V, Callaghan D, Walker D, Lue LF, Liu QY, Couraud PO, Romero IA, Weksler B, Stanimirovic DB, Zhang W, Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis 2009 34 95 106. doi: 10.1016/j.nbd.2008.12.007
18. Deane R, Du Yan S, Submamaryan RK, RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003 9 907 913. doi: 10.1038/nm890
19. Li M, Shang DS, Zhao WD, Tian L, Li B, Fang WG, Zhu L, Man SM, Chen YH, Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. J Immunol 2009 182 5778 5788. doi: 10.4049/jimmunol.0803013
20. Zlokovic BV, Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011 12 723 738. doi: 10.1038/nrn3114
21. Carmeliet P, Jain RK, Molecular mechanisms and clinical applications of angiogenesis. Nature 2011 473 298 307. doi: 10.1038/nature10144
22. Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV, Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010 68 409 427. doi: 10.1016/j.neuron.2010.09.043
23. Wu Z, Guo H, Chow N, Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med 2005 11 959 965. doi: 10.1038/nm1287
24. Paris D, Patel N, DelleDonne A, Quadros A, Smeed R, Mullan M, Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci Lett 2004 366 80 85. doi: 10.1016/j.neulet.2004.05.017
25. Paris D, Townsend K, Quadros A, Inhibition of angiogenesis by Abeta peptides. Angiogenesis 2004 7 75 85. doi: 10.1023/B:AGEN.0000037335.17717.bf
26. Tarasoff-Conway JM, Carare RO, Osorio RS, Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol 2015 11 457 470. doi: 10.1038/nrneurol.2015.119
27. Kester MI, Goos JD, Teunissen CE, Benedictus MR, Bouwman FH, Wattjes MP, Barkhof F, Scheltens P, van der Flier WM, Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. JAMA Neurol 2014 71 855 862. doi: 10.1001/jamaneurol.2014.754
28. la Torre de JC, Cardiovascular risk factors promote brain hypoperfusion leading to cognitive decline and dementia. Cardiovasc Psychiatry Neurol 2012 2012 367516
29. Katusic ZS, Austin SA, Endothelial nitric oxide: protector of a healthy mind. Eur Heart J 2014 35 888 894. doi: 10.1093/eurheartj/eht544
30. Jeynes B, Provias J, Significant negative correlations between capillary expressed eNOS and Alzheimer lesion burden. Neurosci Lett 2009 463 244 248. doi: 10.1016/j.neulet.2009.07.091
31. Verghese PB, Castellano JM, Holtzman DM, Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol 2011 10 241 252. doi: 10.1016/S1474-4422(10)70325-2
32. Hajjar I, Sorond F, Lipsitz LA, Apolipoprotein E, carbon dioxide vasoreactivity, and cognition in older adults: effect of hypertension. J Am Geriatr Soc 2015 63 276 281. doi: 10.1111/jgs.13235
33. Charidimou A, Werring DJ, Cerebral microbleeds and cognition in cerebrovascular disease: an update. J Neurol Sci 2012 322 50 55. doi: 10.1016/j.jns.2012.05.052
34. Schilling S, DeStefano AL, Sachdev PS, APOE genotype and MRI markers of cerebrovascular disease: systematic review and meta-analysis. Neurology 2013 81 292 300. doi: 10.1212/WNL.0b013e31829bfda4
35. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, Berk BC, Zlokovic BV, Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012 485 512 516. doi: 10.1038/nature11087
36. Halliday MR, Pomara N, Sagare AP, Mack WJ, Frangione B, Zlokovic BV, Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown. JAMA Neurol 2013 70 1198 1200. doi: 10.1001/jamaneurol.2013.3841
37. Halliday MR, Rege SV, Ma Q, Zhao Z, Miller CA, Winkler EA, Zlokovic BV, Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease [published online ahead of print March 11, 2015]. J Cereb Blood Flow Metab. doi: 10.1038/jcbfm.2015.44. http://www.nature.com/jcbfm/journal/vaop/ncurrent/full/jcbfm201544a.html
38. Wardlaw JM, Allerhand M, Doubal FN, Valdes Hernandez M, Morris Z, Gow AJ, Bastin M, Starr JM, Dennis MS, Deary IJ, Vascular risk factors, large-artery atheroma, and brain white matter hyperintensities. Neurology 2014 82 1331 1338. doi: 10.1212/WNL.0000000000000312
39. Páll D, Lengyel S, Komonyi E, Molnár C, Paragh G, Fülesdi B, Katona E, Impaired cerebral vasoreactivity in white coat hypertensive adolescents. Eur J Neurol 2011 18 584 589. doi: 10.1111/j.1468-1331.2010.03209.x
40. Østergaard L, Jespersen SN, Engedahl T, Gutiérrez Jiménez E, Ashkanian M, Hansen MB, Eskildsen S, Mouridsen K, Capillary dysfunction: its detection and causative role in dementias and stroke. Curr Neurol Neurosci Rep 2015 15 37. doi: 10.1007/s11910-015-0557-x
41. Strandgaard S, Olesen J, Skinhoj E, Lassen NA, Autoregulation of brain circulation in severe arterial hypertension. Br Med J 1973 1 507 510
42. Qiu C, Winblad B, Fratiglioni L, The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005 4 487 499. doi: 10.1016/S1474-4422(05)70141-1
43. Bath PM, Wardlaw JM, Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions. Int J Stroke 2015 10 469 478. doi: 10.1111/ijs.12466
44. McGuinness B, Craig D, Bullock R, Malouf R, Passmore P, Statins for the treatment of dementia. Cochrane Database Syst Rev 2014 7 CD007514. doi: 10.1002/14651858.CD007514.pub3
45. Jaturapatporn D, Isaac MG, McCleery J, Tabet N, Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2012 2 CD006378. doi: 10.1002/14651858.CD006378.pub2
46. Carlson MC, Tschanz JT, Norton MC, Welsh-Bohmer K, Martin BK, Breitner JC, H2 histamine receptor blockade in the treatment of Alzheimer disease: a randomized, double-blind, placebo-controlled trial of nizatidine. Alzheimer Dis Assoc Disord 2002 16 24 30
47. Lavallée PC, Labreuche J, Gongora-Rivera F, Jaramillo A, Brenner D, Klein IF, Touboul PJ, Vicaut E, Amarenco P, Lacunar-BICHAT Investigators Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease. Stroke 2009 40 1721 1728. doi: 10.1161/STROKEAHA.108.540088
48. Dawson J, Quinn TJ, Harrow C, Lees KR, Walters MR, The effect of allopurinol on the cerebral vasculature of patients with subcortical stroke; a randomized trial. Br J Clin Pharmacol 2009 68 662 668. doi: 10.1111/j.1365-2125.2009.03497.x
49. Hajjar I, Hart M, Chen YL, Mack W, Novak V, C Chui H, Lipsitz L, Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. J Am Geriatr Soc 2013 61 194 201. doi: 10.1111/jgs.12100
50. Suri S, Mackay CE, Kelly ME, Germuska M, Tunbridge EM, Frisoni GB, Matthews PM, Ebmeier KP, Bulte DP, Filippini N, Reduced cerebrovascular reactivity in young adults carrying the APOE ε4 allele. Alzheimers Dement 2015 11 648 57.e1. doi: 10.1016/j.jalz.2014.05.1755
51. Bakker SL, de Leeuw FE, den Heijer T, Koudstaal PJ, Hofman A, Breteler MM, Cerebral haemodynamics in the elderly: the Rotterdam study. Neuroepidemiology 2004 23 178 184. doi: 10.1159/000078503